GSTO2 and ovarian carcinoma: In the study by Morari on Brazilian patients [104], no differences were found between the GSTO2*N142D variant and the risk of ovarian cancer, whereas the same polymorphism was associated with an increased risk of ovarian cancer in a study on a small group of Thai patients [105].